Fundraising Fox
Provectus Biopharmaceuticals
OTC: PVCTKnoxville, US · Delaware corporation
Find your way into Provectus Biopharmaceuticals
Sign up to see every warm intro you have to Provectus Biopharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Provectus Biopharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Provectus is a clinical-stage biotechnology company developing immunotherapy medicines based on small molecules called halogenated xanthenes, with a lead molecule called rose bengal disodium. Its drug platform targets indications across disease areas including oncology, dermatology, hematology, virology, microbiology, and ophthalmology.
Founders & leadership
CD
Craig DeesCo-founder
TC
Timothy C. ScottCo-founder
HR
Heather RainesChief Financial OfficerHeather Raines is Executive Officer at Provectus Biopharmaceuticals, a clinical-stage biotechnology company developing immunotherapy medicines based on small molecules. With over two decades of experience, she has background in accounting operations, financial systems, and cost management.
EA
Eric A. WachterChief Technology Officer
BH
Bruce HorowitzNamed on SEC filing
Board
EP
Edward PershingBoard director
DR
Dominic RodriguesBoard director
JL
John Lacey, IIIBoard director
WB
Webster BaileyBoard director
KM
Kelly M. McMastersBoard director
AE
Alfred E. Smith IVBoard director
Reported raises · per SEC filings
Form D private placements$4.4M disclosed across 4 of 6 rounds · 2011–2024
▶$10MofferedJul 2024 · PharmaceuticalsRule 506(b)
▶$10MofferedJul 2024 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Edward PershingDirector
- Dominic RodriguesDirector
- John Lacey, IIIDirector
- Eric WachterExecutive Officer
- Heather RainesExecutive Officer
- Webster BaileyDirector
- Offering amount
- $10M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$317.5KraisedOct 2022 · 2 investors · PharmaceuticalsRule 506(b)
▶$317.5KraisedOct 2022 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Webster BaileyDirector
- Ed PershingDirector
- Eric WachterExecutive Officer
- Bruce HorowitzExecutive Officer, Director
- John Lacey, IIIDirector
- Dominic RodriguesDirector
- Heather RainesExecutive Officer
- Offering amount
- $5M
- Amount sold
- $317.5K
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedAug 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedAug 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Webster BaileyDirector
- Ed PershingDirector
- Heather RainesExecutive Officer
- Dominic RodriguesDirector
- Eric WachterExecutive Officer
- John Lacey, IIIDirector
- Bruce HorowitzExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $200K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MofferedOct 2014 · PharmaceuticalsRule 506(b)
▶$15MofferedOct 2014 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric A. WachterExecutive Officer
- Tim ScottExecutive Officer
- Peter R. CulpepperExecutive Officer
- Jan KoeDirector
- Kelly M. McMastersDirector
- Alfred E. Smith IVDirector
- H. Craig DeesExecutive Officer, Director
- Offering amount
- $15M
- Placement agents
- Network 1 Financial Securities, Inc.
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedApr 2014 · 17 investors · PharmaceuticalsRule 506(b)
▶$3.4MraisedApr 2014 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kelly M. McMastersDirector
- Peter R. CulpepperExecutive Officer
- H. Craig DeesExecutive Officer, Director
- Alfred E. Smith IVDirector
- Eric A. WachterExecutive Officer
- Timothy C. ScottExecutive Officer, Director
- Jan KoeDirector
- Offering amount
- $5M
- Amount sold
- $3.4M
- Sales commissions
- $334.6K
- Placement agents
- Network 1 Financial Securities, Inc.
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedMar 2012 · 6 investors · PharmaceuticalsRule 506(b)
▶$500KraisedMar 2012 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Eric A. WachterExecutive Officer, Director
- Craig DeesExecutive Officer, Director
- Peter R. CulpepperExecutive Officer
- Kelly M. McMastersDirector
- Alfred E. Smith IVDirector
- Timothy C. ScottExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $500K
- Sales commissions
- $55K
- Placement agents
- Network 1 Financial Securities, Inc.
- First sale
- Sep 2011
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies working in the same space as Provectus Biopharmaceuticals.
In the news
Provectus Biopharmaceuticals (PVCT) narrows loss but flags going concern riskstocktitan.net · Aug 2026Frequently asked questions
- What does Provectus Biopharmaceuticals do?
- Provectus is a clinical-stage biotechnology company developing immunotherapy medicines based on small molecules called halogenated xanthenes, with a lead molecule called rose bengal disodium. Its drug platform targets indications across disease areas including oncology, dermatology, hematology, virology, microbiology, and ophthalmology.
- Who founded Provectus Biopharmaceuticals?
- Provectus Biopharmaceuticals was founded by Craig Dees, Timothy C. Scott.
- How much funding has Provectus Biopharmaceuticals raised?
- Provectus Biopharmaceuticals has disclosed $4.4M raised across 4 of its 6 known rounds.
- Where is Provectus Biopharmaceuticals headquartered?
- Provectus Biopharmaceuticals is headquartered in Knoxville, US.